Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience reports clinical-stage biotechnology developments in microglia-focused treatments for neurodegenerative diseases. Its updates have centered on TREM2 agonist programs, including iluzanebart, a monoclonal antibody TREM2 agonist studied in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, and VG-3927, an oral small molecule TREM2 agonist developed with an initial focus on Alzheimer’s disease.
Recurring disclosures include clinical safety, tolerability, pharmacokinetic and pharmacodynamic data, scientific conference presentations, operating results, material agreements, governance matters and capital-structure updates. The company also reported Phase 2 IGNITE results for iluzanebart in ALSP and the discontinuation of the related long-term extension study after the trial showed no beneficial biomarker or clinical efficacy effects.
Vigil Neuroscience announced the appointment of Christopher Verni as General Counsel and Mary Thistle to its Board of Directors on April 20, 2022. This strategic move is aimed at strengthening the company's leadership during a critical growth phase. Verni brings over 20 years of legal experience in biopharma, previously serving in key roles at Sarepta Therapeutics and ARIAD Pharmaceuticals. Thistle, with over 25 years in biopharmaceutical strategy and financing, has a record of successfully developing and expanding product pipelines. Their expertise is expected to enhance Vigil's efforts in developing innovative therapeutics.
Vigil Neuroscience, Inc. (Nasdaq: VIGL) recently completed a successful IPO, raising $98 million in gross proceeds. In 2021, the company initiated its VGL101 Phase 1 trial and plans to start a Phase 2 trial in ALSP patients in the second half of 2022. Vigil also initiated IND-enabling studies for a small molecule Alzheimer’s disease program. Financially, Vigil reported a net loss of $43.3 million for 2021, up from $28.5 million in 2020, driven by increased R&D expenses. Despite this, the company has cash reserves expected to fund operations into 2024.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on neurodegenerative diseases, announced participation in the Stifel 2022 CNS Days conference. CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will join a fireside chat on March 28, 2022, at 9:45 a.m. ET. This event can be accessed via a live webcast on the Vigil website. The company aims to create precision-based therapies by leveraging microglia, the brain's immune cells, for treating various neurodegenerative conditions.
Vigil Neuroscience (Nasdaq: VIGL) announced two upcoming electronic poster presentations for the 2022 American Academy of Neurology Annual Meeting, detailing findings on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The presentations focus on the lack of genotype-phenotype correlations and survival analysis of ALSP patients. VGL101, Vigil's leading monoclonal antibody, targets TREM2, crucial for microglial function, aiming to address the unmet need of treating ALSP, a rare neurological disease caused by CSF1R gene mutations, affecting approximately 10,000 individuals in the US.
Vigil Neuroscience has successfully closed its initial public offering on January 11, 2022, of 7,000,000 shares priced at $14.00 each, yielding gross proceeds of $98 million. Additionally, underwriters received a 30-day option for up to 1,050,000 more shares at the same price. The shares began trading on the Nasdaq under the symbol VIGL on January 7, 2022. The offering's joint book-running managers include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities.
Vigil Neuroscience, a clinical-stage biotechnology firm, has priced its initial public offering (IPO) at $14.00 per share, offering 7,000,000 shares for a total expected gross proceeds of $98 million. The offering will commence trading on the Nasdaq under the ticker symbol 'VIGL' on January 7, 2022, and is set to close on January 11, 2022, pending customary closing conditions. Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities. This IPO aims to advance Vigil's microglia-focused therapeutics aimed at neurodegenerative diseases.